Amarin (AMRN) Q2 2026 Earnings Call Transcript
Amarin (AMRN) reported Q2 2026 results on an earnings call. Total net revenue was $42.2M, down 42% year over year, mainly due to a $25M upfront licensing payment in 2025. U.S. product revenue fell to $32.2M, while Europe product revenue rose to $5.4M. Operating loss narrowed to $12.0M and cash and investments were $314.6M.
How this was made
The 30-second read
Why it matters
Key investor takeaways are the magnitude of revenue decline driven by the absence of a prior-year upfront licensing payment, continued U.S. pricing pressure despite volume growth, and improving profitability and cash flow supported by a completed restructuring and $70M annual cost savings.
Market read
Traders can update models for AMRN based on quantified Q2 results, the stated full-year 2026 cash outlook, and the confirmation of $70M annual cost savings, while monitoring whether U.S. pricing pressure persists.
What to watch
The call notes higher cost of goods sold from regaining an exclusive PBM relationship and a reliance on partner-driven Europe/Rest-of-World revenue, which could swing margins and cash conversion if partner purchasing timing changes.
Background
Amarin’s Q2 2026 call frames a post-restructuring, scalable model with Europe increasingly royalty and supply-driven through Recordati.
Ticker impact
Amarin reported Q2 2026 revenue of $42.2M, with U.S. product revenue down 12% on generic pricing pressure despite higher volumes.
Likely choppy trading, with upside support from narrowing losses and positive operating cash flow, offset by persistent U.S. pricing pressure.
The call provides multiple quantified datapoints: revenue decline, U.S. pricing pressure, operating loss narrowing, and third consecutive quarter of positive operating cash flow. However, it does not introduce new guidance beyond the stated full-year 2026 cash outlook and cost-savings achievement, limiting directional conviction.
Market effects
Reinforces the ongoing competitive pressure from multi-source generics in icosapent ethyl, while highlighting a shift toward royalty and supply-based economics via partners.
Europe demand growth tied to Recordati shipments may support regional sentiment for branded IPE franchises.
Guideline mentions and partner demand growth can influence expectations for high-risk cardiovascular therapeutics, but the financial impact is company-specific.
Counterpoint
The U.S. market share increase and branded prescription growth could eventually translate into pricing stabilization, making the current revenue decline more temporary than structural.
Key entities
- companyAmarin Corporation plc
Reported Q2 2026 financial results and discussed restructuring completion, cost savings, U.S. pricing pressure, and partner-driven Europe demand.
- partnerRecordati
Partnered in Europe, positioned VAZKEPA as a priority brand and drove royalty and supply shipments referenced in the call.
- advisorBarclays
Named as Amarin’s exclusive financial adviser while it evaluates additional opportunities to enhance shareholder value.
